![](https://endpts.com/wp-content/uploads/2023/03/Rahul-Ballal-Paul-Yaworsky-Mediar-tile.jpg)
Mediar Therapeutics CEO Rahul Ballal (L) and CSO Paul Yaworsky
Five pharmas back $85M Series A for Mediar's fibrosis-modulating antibodies
Mediar Therapeutics nabbed $85 million to get in the clinic next year with its first antibody meant to modulate fibrosis, hence the biotech’s name …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.